A5064051632- Inflammatory Bowel Disease
- Microscopic Colitis
- Liver Diseases and Immunity
- Eosinophilic Esophagitis
- Esophageal and GI Pathology
- Celiac Disease Research and Management
- Gastric Cancer Management and Outcomes
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Esophageal Cancer Research and Treatment
- Biosimilars and Bioanalytical Methods
- Viral-associated cancers and disorders
- Pregnancy and Medication Impact
- Gastrointestinal disorders and treatments
- Eosinophilic Disorders and Syndromes
- T-cell and B-cell Immunology
- Dysphagia Assessment and Management
- Immunodeficiency and Autoimmune Disorders
- Gastroesophageal reflux and treatments
- Autoimmune and Inflammatory Disorders
- Hepatitis C virus research
- Systemic Lupus Erythematosus Research
Indiana University – Purdue University Indianapolis
2016-2018
Indiana University School of Medicine
2016-2018
Indiana University
2017-2018
Saint Louis University
2018
Montefiore Medical Center
2018
We aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, identify predictors response treatment.Retrospective review (May 2014-December 2016) VICTORY Consortium data. Adults with follow-up after starting VDZ clinically active UC were included. Primary outcomes cumulative rates clinical remission (resolution all UC-related symptoms) endoscopic (Mayo sub-score 0). Key secondary included corticosteroid-free deep (clinical remission). Cox proportional hazard...
As more treatment options for inflammatory bowel diseases become available, it is important to identify patients most likely respond different therapies. We created and validated a scoring system with Crohn's disease (CD) who vedolizumab.
There are few real-world data on the safety of vedolizumab for treatment Crohn's disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious non-infectious adverse events in clinical practice.We performed a retrospective review from multicenter consortium database (from May 2014 through June 2017). Infectious were defined as those requiring antibiotics, hospitalization, discontinuation, resulting death. Rates proportions per...
Abstract Background We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness VDZ dose intensification for managing LOR. Methods Retrospective review (May 2014–December 2016) a prospectively maintained inflammatory bowel disease (IBD) registry. Kaplan-Meier estimates were used determine rates LOR . Independent predictors identified using univariate multivariable Cox proportional hazard regression. Success recapturing (>50% reduction...
Conventional approaches to participant recruitment are often inadequate in rare disease investigation. Social networking sites such as Facebook may provide a vehicle circumvent common research limitations and pitfalls. We report our preliminary experience with Facebook-based methodology for participation into an ongoing study of autoimmune hepatitis (AIH).The goal was conduct pilot assess whether is capable recruiting geographically widespread participants AIH patient-oriented obtaining...
Concurrent autoimmune illnesses contribute to increased medical burden and reduced quality of life in patients with hepatitis (AIH). The frequency coexisting conditions among North American AIH their families remains incomplete. Challenges associated disease capture the electronic record, high study costs, geographic spread are formidable barriers understanding extent concurrent these groups.This objective this was examine extrahepatic diseases (EHAD) cases healthy controls as well...
Background: Vedolizumab (VDZ) is now widely used for moderately-severely active ulcerative colitis (UC). Quantifying outcomes and identifying predictors of response would be clinical utility. Methods: Through a multicentre collaboration (US VICTORY consortium), UC patients starting VDZ were pooled across 9 academic sites. The current analyses include with disease (Mayo endoscopic sub-score 2 or 3) within 12 weeks prior to VDZ, at least one follow-up. Response was based on the physician...
Introduction: Vedolizumab (VDZ) is a gut-selective α4β7 integrin monoclonal antibody indicated for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). In clinical studies, VDZ was found to be efficacious as induction maintenance therapy patients (pts) naïve or previously exposed anti-TNFs.1,2 We examined real-world trends in usage practice over 2-year (yr) period retrospective observational cohort pts with inflammatory bowel (IBD). Methods: Through multicenter collaboration...
<sec> <title>BACKGROUND</title> Concurrent autoimmune illnesses contribute to increased medical burden and reduced quality of life in patients with hepatitis (AIH). The frequency coexisting conditions among North American AIH their families remains incomplete. Challenges associated disease capture the electronic record, high study costs, geographic spread are formidable barriers understanding extent concurrent these groups. </sec> <title>OBJECTIVE</title> This objective this was examine...
<sec> <title>BACKGROUND</title> Conventional approaches to participant recruitment are often inadequate in rare disease investigation. Social networking sites such as Facebook may provide a vehicle circumvent common research limitations and pitfalls. We report our preliminary experience with Facebook-based methodology for participation into an ongoing study of autoimmune hepatitis (AIH). </sec> <title>OBJECTIVE</title> The goal was conduct pilot assess whether is capable recruiting...
Background and aims The impact of the advent an institutional endoscopic eradication therapy (EET) program on surgical practice for Barrett's esophagus (BE)-associated high grade dysplasia (HGD) or suspected T1a esophageal adenocarcinoma (EAC) is unknown. this study are to evaluate different modalities used during development our EET factors associated with use surgery these patients after its development. Methods Patients who underwent primary treatment BE-HGD early EAC at hospital between...